Biotech & Drug DiscoveryKOSDAQ 109820162 approvals1 trials

GENEMATRIX INC.

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

As of 2026-10-10, GENEMATRIX INC. has 162 Korean MFDS device approvals, 16 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

GeneMatrix was founded in December 2000 and listed on KOSDAQ in November 2009 as a biotechnology company focused on molecular diagnostics and drug development. Using proprietary core technologies including C-Tag, Encleap, TriO, and RFMP, the company develops and sells molecular diagnostic reagents and biochemical reagents, with its NeoPlex product line covering sexually transmitted infections (STI), tuberculosis and non-tuberculous mycobacteria (TB/NTM), human papillomavirus (HPV), respiratory infections (RI), and gastrointestinal infections (GI) as its core product areas. Its multiplex real-time fluorescence analysis technology (C-Tag) enables real-time pathogen detection during gene amplification, and the company is also developing vaccines and immuno-oncology therapeutics for disease prevention and treatment.

Products & technology

NeoPlexMultiplex molecular diagnostic product line covering sexually transmitted infections (STI), tuberculosis and non-tuberculous mycobacteria (TB/NTM), human papillomavirus (HPV), respiratory infections (RI), and gastrointestinal infections (GI), detecting multiple pathogens at once
Hepatitis B treatment resistance diagnosticDiagnoses resistance to hepatitis B treatment drugs
Hepatitis C virus genotyping diagnosticGenotypes hepatitis C virus
Cervical cancer-causing virus genotyping diagnosticGenotypes the virus that causes cervical cancer

Regulatory approvals

data.go.kr

162 Korean MFDS device approvals · 2007–2026

MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2026-03-31
Product approval · Class 3체외 제허 26-243 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2026-03-31
Product approval · Class 3체외 제허 26-242 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2026-03-31
Product approval · Class 3체외 제허 26-241 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2025-12-17
Product approval · Class 3체외 제허 25-849 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2025-10-21
Product approval · Class 3체외 제허 25-704 호
MFDSClinical chemistry automated analyser2023-07-18
Product approval · Class 1체외 수신 23-1759 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-13
Product approval · Class 3체외 제허 23-343 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-09-05
Product approval · Class 3체외 제허 22-594 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2022-07-20
Product approval · Class 3체외 제허 22-469 호
MFDSClinical chemistry automated analyser2022-05-24
Product approval · Class 1체외 수신 22-913 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-11-10
Product approval · Class 3체외 제허 21-896 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-08-27
Product approval · Class 3체외 제허 21-729 호

Show 68 more

MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2021-07-27
Product approval · Class 3체외 제허 21-636 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-07-12
Product approval · Class 3체외 제허 21-586 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-07-01
Product approval · Class 3체외 제허 21-543 호
MFDSClinical chemistry automated analyser2021-05-11
Product approval · Class 1체외 수신 21-827 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-10-05
Product approval · Class 3체외 제허 20-857 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-09-29
Product approval · Class 3체외 제허 20-849 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide use2020-08-26
Product approval · Class 3체외 제허 20-744 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide use2020-08-26
Product approval · Class 3체외 제허 20-743 호
MFDSGeneral calibrators, controls or standards, classⅢ, for clinical chemistryRevoked2020-08-26
Product approval · Class 3체외 제허 20-742 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide use2020-08-26
Product approval · Class 3체외 제허 20-741 호
MFDSGeneral calibrators, controls or standards, classⅢ, for clinical chemistryRevoked2020-08-26
Product approval · Class 3체외 제허 20-739 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide use2020-08-26
Product approval · Class 3체외 제허 20-740 호
MFDSGeneral calibrators, controls or standards, classⅢ, for clinical chemistryRevoked2020-08-26
Product approval · Class 3체외 제허 20-749 호
MFDSGeneral calibrators, controls or standards, classⅢ, for clinical chemistryRevoked2020-08-26
Product approval · Class 3체외 제허 20-748 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-26
Product approval · Class 3체외 제허 20-747 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-26
Product approval · Class 3체외 제허 20-746 호
MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-26
Product approval · Class 3체외 제허 20-745 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide use2020-08-11
Product approval · Class 2체외 제인 20-4739 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide use2020-08-11
Product approval · Class 2체외 제인 20-4737 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide use2020-08-11
Product approval · Class 2체외 제인 20-4736 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-11
Product approval · Class 2체외 제인 20-4735 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-11
Product approval · Class 2체외 제인 20-4734 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4728 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4727 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4726 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4725 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4724 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide useRevoked2020-08-10
Product approval · Class 2체외 제인 20-4723 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide use2020-08-10
Product approval · Class 2체외 제인 20-4722 호
MFDSGeneral Calibrators, controls or standards, classⅡ, for clinical immunology, not a component of specific kit, wide use2020-08-10
Product approval · Class 2체외 제인 20-4729 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-06-03
Product approval · Class 3체외 제허 20-438 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-04-28
Product approval · Class 3체외 제허 20-336 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-03-20
Product approval · Class 3체외 제허 20-199 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-03-16
Product approval · Class 3체외 제허 20-184 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2019-12-19
Product approval · Class 3체외 제허 19-827 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2019-03-27
Product approval · Class 3체외 제허 19-190 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2018-11-14
Product approval · Class 1체외 제신 18-1526 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2018-11-06
Product approval · Class 3체외 제허 18-722 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2018-09-04
Product approval · Class 1체외 제신 18-1148 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2018-07-27
Product approval · Class 3체외 제허 18-538 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2018-07-17
Product approval · Class 3체외 제허 18-503 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2018-05-17
Product approval · Class 1체외 제신 18-619 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2017-11-02
Product approval · Class 3체외 제허 17-834 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2017-07-11
Product approval · Class 3체외 제허 17-484 호
MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2017-02-15
Product approval · Class 3체외 제허 17-115 호
MFDSIVD reagents for general immune testRevoked2016-09-27
Product approval · Class 2체외 제인 16-721 호
MFDSIVD reagents for general immune testRevoked2016-09-23
Product approval · Class 2체외 제인 16-716 호
MFDSFluorimetric immunoassay analyzer(FIA), stationary2016-09-12
Product approval · Class 1체외 수신 16-2388 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-06-16
Product approval · Class 1체외 제신 16-739 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-06-16
Product approval · Class 1체외 제신 16-738 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-04-21
Product approval · Class 1체외 제신 16-489 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-03-10
Product approval · Class 1체외 제신 16-291 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-03-10
Product approval · Class 1체외 제신 16-289 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-03-10
Product approval · Class 1체외 제신 16-288 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-03-10
Product approval · Class 1체외 제신 16-287 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2016-03-10
Product approval · Class 1체외 제신 16-286 호
MFDSIVD reagents for infectious inflammatory testsRevoked2015-07-23
Product approval · Class 2체외 제인 15-1223 호
MFDSIVD reagents for autoimmune diseaseRevoked2015-06-18
Product approval · Class 2체외 제인 15-965 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-05-29
Product approval · Class 1경인 체외 제신 15-279 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-05-29
Product approval · Class 1경인 체외 제신 15-278 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-04-24
Product approval · Class 1경인 체외 제신 15-193 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-04-24
Product approval · Class 1경인 체외 제신 15-192 호
MFDSIVD reagents for general immune test2015-01-14
Product approval · Class 2체외 제인 15-49 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-01-09
Product approval · Class 1경인 체외 제신 15-12 호
MFDSGeneral calibrators, controls or standards, classⅠ, for clinical chemistryRevoked2015-01-09
Product approval · Class 1경인 체외 제신 15-11 호
MFDSIVD reagents for autoimmune diseaseRevoked2014-11-19
Product approval · Class 2체외 제인 14-2303 호
MFDSIVD reagents for general immune test2014-11-19
Product approval · Class 2체외 제인 14-2304 호
MFDSIVD reagents for general immune test2014-03-13
Product approval · Class 2체외 제인 14-608 호

Showing the 80 most recent of 162 records.

Clinical trials

data.go.kr

1 MFDS clinical trial authorisations · 2025 (Phase 1 1)

Phase 1GMAI-022025-04-18
1 trial site

Key disclosures

KRX KIND via OpenDART

Management투자판단관련주요경영사항(임상시험계획자진취하등) (GMJI-01의 국내 제1상 임상시험계획 승인신청 자진취하)2025-06-16
Contract[기재정정]단일판매ㆍ공급계약체결2025-06-02
Management투자판단관련주요경영사항(임상시험계획승인신청등결정) (GMAI-02의 국내 제1상 임상시험계획승인)2025-04-21
Contract[기재정정]단일판매ㆍ공급계약체결2025-04-14
Contract[기재정정]단일판매ㆍ공급계약체결2025-04-02
Contract[기재정정]단일판매ㆍ공급계약체결2025-04-02
Contract[기재정정]단일판매ㆍ공급계약체결2025-03-21
Contract[기재정정]단일판매ㆍ공급계약체결2025-03-10
Management투자판단관련주요경영사항(임상시험계획승인신청)2024-12-23
Management투자판단관련주요경영사항(임상시험계획승인신청) (GMAI-02의 국내 제1상 임상시험계획승인 신청)2024-11-18

Publications

PubMed · affiliation-matched

Protective efficacy of GMAI-02, a cDNA-derived inactivated hepatitis A vaccine, against HM175/mp7 challenge in interferon-receptor-deficient mice.
Virology · 2026-06 · Chung YJ, Oh HS, Kim SO 외 1
Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response.
Virology · 2024-12 · Jang SO, Lee JH, Chung YJ 외 4
A purified inactivated vaccine derived from Vero cell-adapted zika virus elicits protection in mice.
Virology · 2021-08 · Oh HS, Yoon JW, Lee S 외 2
Comparative Clinical Evaluation of NeoPlex RB-8 with Seeplex PneumoBacter ACE for Simultaneous Detection of Eight Respiratory Bacterial Pathogens.
Journal of clinical microbiology · 2020-01 · Kim JW, Hong SS, Lee IS 외 4
Triticum aestivum ethanolic extract improves non-alcoholic fatty liver disease in mice fed a choline-deficient or high-fat diet.
Journal of the science of food and agriculture · 2019-03 · Oh HS, Cho W, Tak SB 외 3
Comparison of the clinical performance of OmniPlex-HPV and GeneFinder HPV for the detection and genotyping of human papillomaviruses in cervical specimens.
Journal of medical microbiology · 2018-09 · Hong G, Park YG, Jin HW 외 6
Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.
Liver international : official journal of the International Association for the Study of the Liver · 2015-11 · Chon YE, Jin B, Ahn SH 외 10
Loss of mismatched HLA detected in the peripheral blood of an AML patient who relapsed after haploidentical hematopoietic stem cell transplantation.
Annals of laboratory medicine · 2015-09 · Park BG, Sohn YH, Oh HB 외 3
Performance evaluation of the TheraTyper-GJB2 assay for detection of GJB2 gene mutations.
The Journal of molecular diagnostics : JMD · 2014-09 · Chun JY, Shin SK, Min KT 외 4
Multiplex detection of KRAS mutations by a matrix-assisted laser desorption/ionization-time of flight mass spectrometry assay.
Clinical biochemistry · 2014-08 · Choi HS, Min KT, Cha YS 외 1

Show 6 more publications

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.
Clinical and molecular hepatology · 2013-12 · Ahn SH, Chun JY, Shin SK 외 5
Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2013-06 · Lee JH, Hachiya A, Shin SK 외 10
Analysis of TPOX short tandem repeat locus with matrix-associated laser desorption/ionization time-of-flight-based restriction fragment mass polymorphism assay.
Analytical biochemistry · 2011-05 · Cha YS, Choi SH, Lee JH 외 5
A simple and accurate SNP scoring strategy based on typeIIS restriction endonuclease cleavage and matrix-assisted laser desorption/ionization mass spectrometry.
BMC genomics · 2008-06 · Hong SP, Ji SI, Rhee H 외 7
High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry.
Nature protocols · 2008-01 · Hong SP, Shin SK, Lee EH 외 7
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.
Journal of hepatology · 2004-05 · Hong SP, Kim NK, Hwang SG 외 8

Patents

KIPRIS · applicant-matched

PCR METHOD FOR DETECTING AT LEAST TWO MULTI-TARGET NUCLEIC ACIDS WITH SINGLE SIGNAL
PCT · Published · 2024-06 · Application PCT/KR2024/008885
단일 신호로 2가지 이상의 다중 표적핵산을 검출하기 위한 PCR 방법
Registered · 2023-07 · Application 1020230085510
RECOMBINANT EXPRESSION VECTOR FOR PREVENTION OF SARS-COV-2 INFECTION AND APPLICATION THEREOF
PCT · Published · 2023-02 · Application PCT/KR2023/002808
사스-코로나바이러스-2 감염증 예방용 재조합 발현 벡터 및 그 응용
Registered · 2023-02 · Application 1020230024283
RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF
US · Published · 2022-03 · Application 18551261
RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF
EP · Published · 2022-03 · Application 22781492.8
RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF
PCT · Published · 2022-03 · Application PCT/KR2022/004159
침팬지 아데노바이러스 혈청형 6의 돌기 유전자로 치환된 재조합 키메릭 아데노바이러스 벡터 및 그 응용
Registered · 2022-03 · Application 1020220034885
A형 간염 바이러스 항원 단백질 및 이를 포함하는 백신 조성물
Rejected · 2021-12 · Application 1020210186161
Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein
US · Registered · 2021-05 · Application 17924177

Show 53 more patents

STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEIN
EP · Published · 2021-05 · Application 21811833.9
STRUCTURALLY MODIFIED CHIMERIC POLYPEPTIDE OF HUMAN PAPILLOMAVIRUS, RECOMBINANT PROTEIN COMPRISING SAME POLYPEPTIDE, AND USE OF SAME PROTEIN
PCT · Published · 2021-05 · Application PCT/KR2021/006075
사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도
Registered · 2021-05 · Application 1020210059219
METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCE USING CLEAVED COMPLEMENTARY TAG FRAGMENT AND A COMPOSITION THEREFOR
US · Published · 2020-12 · Application 17115740
모기 매개 바이러스 검출용 프라이머 및 프로브, 및 이를 이용한 모기 매개 바이러스의 검출 방법
Registered · 2020-09 · Application 1020200116311
ZIKA VIRUS VARIANT AND ZIKA VACCINE COMPOSITION COMPRISING SAME
PCT · Published · 2019-06 · Application PCT/KR2019/007265
지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
Registered · 2019-06 · Application 1020190071482
COMPOSITION FOR SOLUBILIZING RECOMBINANT PROTEIN OF E. COLI-DERIVED ZIKA VIRUS ENVELOPE PROTEIN DOMAIN III, AND METHOD FOR PRODUCING ZIKA RECOMBINANT PROTEIN BY USING SAME
PCT · Published · 2019-04 · Application PCT/KR2019/004815
대장균 유래 지카바이러스 외피 단백질 도메인 III 재조합 단백질의 가용화를 위한 조성물 및 이를 이용한 지카 재조합 단백질 생산방법
Registered · 2018-05 · Application 1020180060635
밀순 추출물을 유효성분으로 함유하는 비알코올성 지방간 질환 예방 또는 개선을 위한 조성물
Rejected · 2017-09 · Application 1020170111600
METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCE USING CLEAVED COMPLEMENTARY TAG FRAGMENT AND COMPOSITION THEREOF
CN · Published · 2017-04 · Application 201780025886.7
Method for detecting target nucleic acid sequence using cleaved complementary tag fragment and a composition therefor
US · Registered · 2017-04 · Application 16095695
METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCE USING CLEAVED COMPLEMENTARY TAG FRAGMENT AND COMPOSITION THEREOF
EP · Registered · 2017-04 · Application 17789853.3
METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCE USING CLEAVED COMPLEMENTARY TAG FRAGMENT AND COMPOSITION THEREOF
PCT · Published · 2017-04 · Application PCT/KR2017/004297
切断された相補的なタグ切片を用いた標的核酸配列の検出方法及びその組成物
JP · Registered · 2017-04 · Application 30556900
절단된 상보적인 태그 절편을 이용한 표적 핵산 서열 검출 방법 및 그 조성물
Registered · 2017-04 · Application 1020170049845
심장형 지방산 결합 단백에 특이적인 단일클론항체와 이를 생산하는 하이브리도마 세포 및 그의 제조방법
Expired · 2016-04 · Application 1020160050308
간세포암 환자의 소라페닙 반응을 예측하는 유전자 마커 및 그 이용
Rejected · 2016-03 · Application 1020160033879
재조합 단백질의 가용화를 위한 조성물, 그 방법 및 이를 이용한 재조합 항원의 생산 방법
Registered · 2016-03 · Application 1020160026434
GENE TARGET SITE SEQUENCING METHOD AND SEQUENCING COMPOSITION THEREFOR
PCT · Published · 2014-05 · Application PCT/KR2014/004872
유전자 표적부위 염기서열분석방법 및 그 분석용 조성물
Expired · 2014-05 · Application 1020140064639
PRIMER ABLE TO REGULATE ACTIVITY BY MEANS OF DNA RESTRICTION ENZYME
PCT · Published · 2014-04 · Application PCT/KR2014/003549
DNA 제한효소에 의해 활성 조절이 가능한 프라이머 및 이를 이용한 유전자 증폭방법 그리고 이러한 프라이머의 설계방법
Registered · 2013-04 · Application 1020130048189
Composition for treating and preventing obesity, containing wheatgrass extract as active ingredient
US · Published · 2012-11 · Application 14353240
Composition Containing Triticum Aestivum Lamarck Leaf Extract or Fraction Thereof as Active Ingredient
US · Published · 2012-10 · Application 14353373
표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 PCR 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법
Rejected · 2012-05 · Application 1020120054340
ANALYSIS KIT FOR HIGH-RISK HUMAN PAPILLOMAVIRUS GENES, AND ANALYSIS METHOD THEREFOR
PCT · Published · 2012-05 · Application PCT/KR2012/003588
고위험군 인유두종바이러스 유전자 분석용 키트 및 그 분석방법
Expired · 2012-05 · Application 1020120048467
만성 B형 간염 치료제의 약제내성 예측용 조성물 및 그 예측 방법
Expired · 2012-04 · Application 1020120035603
METHOD USING RESTRICTION FRAGMENT MASS POLYMORPHISM TO DETECT GENETIC MUTATION THAT CAUSES HIV DRUG RESISTANCE
PCT · Published · 2012-04 · Application PCT/KR2012/002441
METHOD FOR ANALYZING THE RISK OF HEPATOMA ONSET FOR CHRONIC PATIENTS OF HEPATITIS TYPE B, AND METHOD OF PREDICTING SAME
PCT · Published · 2012-04 · Application PCT/KR2012/002436
제한효소 절편 질량다형성법을 이용하여 HIV에 대한 약제 내성 유전자 돌연변이 검출방법
Rejected · 2012-03 · Application 1020120033068
METHOD FOR ANALYZING AND PREDICTING RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B
PCT · Published · 2011-10 · Application PCT/KR2011/007895
RNA 변이 분석방법
Expired · 2011-05 · Application 1020110042820
Primer composition for amplifying a gene region having diverse variations in a target gene
CN · Published · 2011-04 · Application 201180033690
PRIMER COMPOSITION FOR AMPLIFYING A GENE REGION HAVING VARIOUS VARIATIONS IN A TARGET GENE
US · Published · 2011-04 · Application 13696694
METHOD FOR PRODUCING AN AMPLICON COMPRISING A GENE REGION HAVING VARIOUS VARIATIONS AND BEING USEFUL IN MASS SPECTROMETRY
EP · Registered · 2011-04 · Application 11777513.0
PRIMER COMPOSITION FOR AMPLIFYING A GENE REGION HAVING DIVERSE VARIATIONS IN A TARGET GENE
PCT · Published · 2011-04 · Application PCT/KR2011/002805
만성 B형 간질환 환자의 간세포암 발병 위험도 분석 및 예측방법
Expired · 2011-04 · Application 1020110033944
항암 및 항암 보조제 조성물
Expired · 2011-04 · Application 1020110030931
만성 B형 간질환 환자의 간세포암 발병 위험도 분석 및 예측방법
Expired · 2010-11 · Application 1020100116880
표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 PCR 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법
Registered · 2010-05 · Application 1020100043166
제한효소 절편 질량다형성법을 이용한 윌슨병 원인 유전자 변이 검출방법
Expired · 2009-01 · Application 1020090007566
다중 염기변이 분석방법
Expired · 2008-08 · Application 1020080077043
Primer for analyzing gene mutation
CN · Published · 2003-10 · Application 200910207600
Method for detecting mutation
CN · Published · 2003-10 · Application 200910208801
Method for detecting mutations
EP · Published · 2003-10 · Application 10001770.6
METHOD FOR DETECTING MUTATIONS
EP · Published · 2003-10 · Application 03754223.0
METHOD FOR DETECTING MUTATIONS
PCT · Published · 2003-10 · Application PCT/KR2003/002179
염기변이 분석방법
Expired · 2003-09 · Application 1020030061066
MTHFR 유전자 변이 분석용 프라이머 및 그프라이머를 이용한 인간 MTHFR 유전자 변이 관련질병 진단방법
Rejected · 2002-12 · Application 1020020083373
염기변이 분석 프라이머 및 그 방법
Expired · 2002-09 · Application 1020020058375
뇌졸중을 예진 또는 진단하는 방법
Rejected · 2001-02 · Application 1020010005824

AI reads

MAA server logs · IP-verified

243

Times AI engines pulled GENEMATRIX INC.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

241

Index crawls

Collected as raw material for future answers.

Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

live 1

Last 7 days

218

live 2

Last 30 days

243

live 2

All time

OpenAIChatGPT-Userlive2
OpenAIOAI-SearchBot213
GoogleGoogleOther16
PerplexityPerplexityBot10
AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for GENEMATRIX INC. and every listed Korean medical, bio and AI company.

How to connect (MCP)

Not yet compiled: business overview · R&D. Send us materials and we will add them

Company facts

Founded: 2000
Listed: 2009
Market: KOSDAQ 109820
CEO: 김수옥
Location: Gyeonggi
Category: Biotech & Drug Discovery

Performance

Separate · DART

Year	Revenue	Op. profit
2025	₩10.6B	-₩679M
2024	₩10.0B	-₩1.6B
2023	₩9.8B	-₩2.5B

AI visibility

2026-10-01

85/ 100

✓Crawler access

✗Structured data

✓Sitemap

✓HTTPS

✓English pages

✗llms.txt

Keywords

molecular-diagnosticsmultiplex-pcrinfectious-diseasehpvhepatitisvaccineimmuno-oncology

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.19 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

GC Medical Science Corporation15 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

DONG-A ST CO.,LTD14 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

SD BIOSENSOR INC.14 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

NanoenTek,Inc.12 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

HUMASIS CO., LTD.12 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

OSANG HEALTHCARE CO.,LTD.12 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Sugentech, Inc.11 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

Access Bio, Inc.9 shared

Founded in 2002 and KOSDAQ-listed in 2013, Access Bio develops rapid diagnostic tests for malaria, COVID-19, and other infectious diseases.

AHN-GOOK PHARMACEUTICAL Co., Ltd.8 shared

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

Precision Biosensor Inc.8 shared

KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.

i-SENS, Inc.7 shared

Founded in 2000 and KOSDAQ-listed in 2013, i-SENS makes blood glucose monitors and point-of-care testing devices.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
Approvals & clinical trials: Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures: KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials: ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials: DART corporate disclosure filings — annual
Publications: PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents: KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads: Our server logs, IP-verified every 6 hours
AI visibility: Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition